BF Biosciences Limited (PSX:BFBIO)

Pakistan flag Pakistan · Delayed Price · Currency is PKR
131.13
-7.73 (-5.57%)
At close: Mar 9, 2026
-23.79%
Market Cap 11.58B
Revenue (ttm) 8.22B
Net Income (ttm) 598.64M
Shares Out 88.33M
EPS (ttm) 6.78
PE Ratio 19.34
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 323,859
Average Volume 417,841
Open 134.99
Previous Close 138.86
Day's Range 124.97 - 135.11
52-Week Range 117.00 - 194.90
Beta n/a
RSI 30.58
Earnings Date Feb 25, 2026

About BF Biosciences

BF Biosciences Limited, a biotech pharmaceutical company, manufactures, imports, and sells pharmaceutical products in Pakistan, Nepal, Afghanistan, Mauritania, Switzerland, and internationally. The company offers pharmaceutical products for various therapeutic areas, including cardiometabolic disorders, cardiology, diabetes, anti-obesity, hepatology, gastroenterology, chronic kidney diseases, dermatology, antifungal treatments, antibiotics, antivirals, rheumatoid arthritis, nephrology, and oncology. It also provides injectables in vials, ampoul... [Read more]

Industry Pharmaceutical Preparations
Founded 2006
Employees 535
Stock Exchange Pakistan Stock Exchange
Ticker Symbol BFBIO
Full Company Profile

Financial Performance

In fiscal year 2025, BF Biosciences's revenue was 5.84 billion, an increase of 59.55% compared to the previous year's 3.66 billion. Earnings were 447.15 million, an increase of 16.02%.

Financial Statements

News

There is no news available yet.